Tenax Therapeutics (TENX) Accumulated Expenses (2011 - 2026)

Tenax Therapeutics has reported Accumulated Expenses for 15 years, with the latest figure at $1.3 million in Q2 2026.

• Accumulated Expenses for Q2 2026 came in at $1.3 million, down 34.96% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.3 million (down 34.96% YoY), and the FY2025 annual result was $1.1 million, down 27.41% from the prior year.
• Accumulated Expenses declined to $1.3 million in Q2 2026, from $2.1 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.1 million in Q1 2026 and troughed at $271633.0 in Q2 2023.
• A 5-year average of $891132.6 and a median of $852022.5 in 2022 frame the typical range for Accumulated Expenses.
• The widest annual swing landed in 2022, when Accumulated Expenses tumbled 38.05%; it then soared 233.68% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $775045.0 in 2022, then soared by 30.7% to $1.0 million in 2023, then surged by 51.63% to $1.5 million in 2024, then slipped by 27.41% to $1.1 million in 2025, then increased by 14.62% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $1.3 million in Q2 2026, $2.1 million in Q1 2026, and $1.1 million in Q4 2025.